01—Abstract
Summary
Summary of the 10-Q filed November 1, 2024. Cited figures are marked; the original filing is the authoritative source.
Thermo Fisher Scientific Inc. reported steady revenue performance for the third quarter of fiscal year 2024, with total revenues reaching $10.598 billiona, largely in line with the prior year's $10.574 billion.
For the nine-month period, revenues saw a slight decrease of 2% to $31.484 billionb from $31.971 billion in the prior year. The company experienced a year-over-year decrease in diluted EPS for the quarter to $4.25 from $4.42, but a growth in diluted EPS for the nine-month period to $11.75 from $11.25. This performance reflects a normalization of COVID-19 related demand and a challenging macroeconomic environment impacting revenue growth across several segments, particularly Life Sciences Solutions and Laboratory Products and Biopharma Services.
The company continues to strategically invest in innovation and commercial capabilities. The acquisition of Olink Holding AB in July 2024 for $3.146 billionc, focused on enhancing its proteomics capabilities within the Life Sciences Solutions segment, is a key strategic move.
Despite revenue headwinds from declining COVID-19 related demand, the company is demonstrating operational resilience with strong productivity improvements and cost management, as evidenced by the growth in GAAP operating income for the nine-month period and a solid operating margin. Management remains confident in its ability to meet future cash requirements through existing cash, operating cash flow, and available credit, while continuing to return capital to shareholders through share repurchases and dividends.
02—Key points
Key Highlights
- Total revenues for the third quarter of 2024 were $10.598 billion, a slight increase of 0% year-over-year.
- GAAP diluted EPS for the third quarter decreased to $4.25 from $4.42 in the prior year, while nine-month diluted EPS increased to $11.75 from $11.25.
- Acquired Olink Holding AB for $3.146 billion in July 2024, bolstering the Life Sciences Solutions segment with proteomics capabilities.
- Operating income for the nine months ended September 28, 2024, increased by 6% to $5.321 billion.
- Free cash flow for the nine months increased by 22% to $4.498 billion compared to the prior year.
- The company repurchased $3.00 billion of common stock in the first nine months of 2024 and has $1.00 billion remaining on its repurchase authorization.
- Organic revenue growth was flat for the third quarter and down 2% for the first nine months, reflecting the post-COVID normalization and macroeconomic challenges.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2024filed November 1, 2024Financial Statements
Q3 FY2024 against Q3 FY2023
| Line item | Q3 FY2024Q3 FY2023 | Change |
|---|---|---|
| Revenue | $10.60B$10.57B | +0.2% |
| R&D Expenses | $346.00M$319.00M | +8.5% |
| SG&A Expenses | $2.10B$2.05B | +2.4% |
| Operating Expenses | $8.76B$8.71B | +0.6% |
| Operating Income | $1.84B$1.86B | −1.4% |
| Net Income | $1.63B$1.72B | −5.0% |
| EPS (Basic) | $4.26$4.44 | −4.1% |
| EPS (Diluted) | $4.25$4.42 | −3.8% |
| Shares Outstanding (Basic) | 382.00M386.00M | −1.0% |
| Shares Outstanding (Diluted) | 384.00M388.00M | −1.0% |
05—Questions
Frequently Asked Questions
What is the primary driver for the revenue stagnation in the third quarter?
The primary driver for the revenue stagnation in the third quarter of 2024 is the ongoing normalization of demand for COVID-19 related products and services, coupled with a challenging macroeconomic environment that has impacted various end markets.
How is Thermo Fisher managing the decline in COVID-19 related revenue?
Thermo Fisher is focusing on its core growth strategy pillars: high-impact innovation, trusted customer partnerships, and its commercial engine. They are also emphasizing productivity improvements and cost management to offset the impact of declining COVID-19 revenue and maintain profitability.
What is the significance of the Olink acquisition?
The acquisition of Olink Holding AB for $3.146 billion significantly enhances Thermo Fisher's capabilities in the high-growth proteomics market within its Life Sciences Solutions segment. It is expected to complement existing offerings and create strong synergy opportunities in protein biomarker discovery.
How is the company managing its debt obligations?
Thermo Fisher maintains a robust liquidity position with significant cash and cash equivalents, along with an undrawn revolving credit facility. The company has a diversified debt structure with various senior notes across different currencies and maturities. While total debt has increased slightly, the company's financial covenants remain strong, and it generated substantial free cash flow to manage its obligations and return capital to shareholders.
06—Continue